Back

Efficacy and safety of zilebesiran for inadequately controlled hypertension: a systematic review and meta-analysis

28 August 2026 (09:15 - 09:40)
Organised by: Logo
Congress Presentation Part of: Contemporary pharmacotherapy for hypertension Aldosterone Antagonists ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Mr Thiago Bonafe

Varzea Grande (Brazil)

3 More presentations in this session

Presentation thumbnail
Risk of incident gout and major adverse cardiovascular events according to angiotensin receptor blocker type in amlodipine-based combination therapy: a nationwide cohort study
Assistant Professor S. Bae (Yongin, KR)
Abstract Slides
Presentation thumbnail
Female-biased renin release in response to relaxin in isolated rat renal cortex: potential implications for RAAS-mediated congestion with relaxin analogues
Professor M. Ufnal (Warsaw, PL)
Abstract Slides
Presentation thumbnail
Comparative efficacy and safety of nebivolol in hypertension: a systematic review and network meta-analysis
Doctor D. Rammahy (Oakville, CA)
Abstract Slides

Access the full session

Session thumbnail
Contemporary pharmacotherapy for hypertension

The Event

Event poster

ESC Congress 2026

28 August 2026 09:15 CET
You may be interested in
thumbnail
Congress Presentation
Add-on treatment with zilebesiran for inadequately controlled hypertension: KARDIA-2 RCT
1 September 2025
thumbnail
Congress Presentation
Comparative effectiveness of novel anti-hyperlipidemic drugs in adults with hyperlipidemia: a systematic review and bayesian network meta-analysis
4 April 2025
thumbnail
Congress Presentation
Tailored interventions to improve adherence to antihypertensive treatment and reduce blood pressure: findings from a systematic review and meta-analysis
5 April 2025
thumbnail
Congress Presentation
Risk of hyperkalemia with sacubitril/valsartan vs. RAAS inhibitor use in heart failure with reduced and preserved ejection fraction: a meta-analysis of 6 RCTs including 17,362 patients
29 June 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources